Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans
- 1 January 2003
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 43 (1) , 84-91
- https://doi.org/10.1177/0091270002239710
Abstract
The metabolic activity of CYP2C9 in 16 subjects expressing four different genotypes (CYP2C9*1/*1, *1/*2, *1/*3, and *2/*2) was evaluated. Single oral doses of tolbutamide, flurbiprofen, and losartan ...Keywords
This publication has 25 references indexed in Scilit:
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and InhibitorsDrug Metabolism Reviews, 1997
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- [15] Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9Published by Elsevier ,1996
- Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofenBiochemical Pharmacology, 1995
- Clinical Pharmacokinetics of Flurbiprofen and its EnantiomersClinical Pharmacokinetics, 1995
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Fitting straight lines when both variables are subject to errorLife Sciences, 1978